{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:19:35Z","timestamp":1793945975525,"version":"4.8.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.diabres.2023.111018","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T15:57:38Z","timestamp":1699977458000},"page":"111018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist na\u00efve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study"],"prefix":"10.1016","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-9596","authenticated-orcid":false,"given":"Tatjana","family":"Milenkovikj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Chekorova Mitreva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Jovanovska Mishevska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iskra","family":"Bitoska-Mileva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Ahmeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2023.111018_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2023.111018_b0010","first-page":"11","article-title":"Diabetes comorbidities in low-and middle-income countries: an umbrella review","author":"Lam","year":"2021","journal-title":"J. Glob. Health"},{"key":"10.1016\/j.diabres.2023.111018_b0015","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3889\/oamjms.2020.5071","article-title":"Growing prevalence and incidence of diabetes in republic of macedonia in the past 5 years based on data from the national system for electronic health records","volume":"8","author":"Ahmeti","year":"2020","journal-title":"Open Access Macedonian J. Med. Sci."},{"key":"10.1016\/j.diabres.2023.111018_b0020","article-title":"Standards of Care in Diabetes\u20142023","volume":"46","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.111018_b0025","first-page":"197","article-title":"Challenges and opportunities in managing type 2 diabetes","volume":"10","author":"Morgan","year":"2017","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.diabres.2023.111018_b0030","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2023.111018_b0035","unstructured":"Food and Drug Administration. Ozempic\u00ae Prescribing Information. 2017; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf."},{"key":"10.1016\/j.diabres.2023.111018_b0040","unstructured":"European Medicines Agency. Ozempic\u00ae Summary of Product Characteristics. 2022; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf."},{"key":"10.1016\/j.diabres.2023.111018_b0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.diabres.2023.111018_b0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.diabres.2023.111018_b0055","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.111018_b0060","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.diabres.2023.111018_b0065","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.diabres.2023.111018_b0070","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabres.2023.111018_b0075","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.diabres.2023.111018_b0080","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.diabres.2023.111018_b0085","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.diabres.2023.111018_b0090","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.diabres.2023.111018_b0095","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/dom.14765","article-title":"Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial","volume":"24","author":"Kellerer","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.diabres.2023.111018_b0100","first-page":"32","article-title":"Semaglutide: a new GLP-1 analogue for type 2 diabetes","volume":"30","author":"Chaplin","year":"2019","journal-title":"Prescriber"},{"key":"10.1016\/j.diabres.2023.111018_b0105","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1111\/dom.13816","article-title":"Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials","volume":"21","author":"Jendle","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.diabres.2023.111018_b0110","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/dom.14039","article-title":"Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)","volume":"22","author":"J\u00f3dar","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.diabres.2023.111018_b0115","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1111\/dom.13331","article-title":"Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1\u20135 trials","volume":"20","author":"Warren","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.diabres.2023.111018_b0120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/dom.13896","article-title":"Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: a patient-level, pooled analysis of the SUSTAIN 1\u20135 trials","volume":"22","author":"Aroda","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.diabres.2023.111018_b0125","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(20)30313-2","article-title":"Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1\u20137 randomised controlled trials","volume":"8","author":"Mann","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.diabres.2023.111018_b0130","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.pcd.2021.06.008","article-title":"Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark\/Sweden multicentre, prospective, observational study","volume":"15","author":"Ekberg","year":"2021","journal-title":"Prim. Care Diabetes"},{"key":"10.1016\/j.diabres.2023.111018_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108931","article-title":"Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study","volume":"178","author":"Rudofsky","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.diabres.2023.111018_b0140","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1111\/dom.14468","article-title":"Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study","volume":"23","author":"Yale","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.diabres.2023.111018_b0145","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.3390\/jcm11174938","article-title":"Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE Spain multicentre, prospective, observational study","volume":"11","author":"Bellido","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.diabres.2023.111018_b0150","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1007\/s13300-021-01141-8","article-title":"Real-world use of once-weekly semaglutide in type 2 diabetes: results from the SURE UK multicentre, prospective, observational study","volume":"12","author":"Holmes","year":"2021","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.diabres.2023.111018_b0155","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-022-02385-x","article-title":"Once-weekly semaglutide use in type 2 diabetes: real-world data from the SURE Netherlands observational study","volume":"40","author":"Wolffenbuttel","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.diabres.2023.111018_b0160","doi-asserted-by":"crossref","DOI":"10.1111\/dom.15020","article-title":"Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study","author":"Napoli","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.diabres.2023.111018_b0165","first-page":"205","article-title":"Real-world use of once-weekly semaglutide in type 2 diabetes: results from SemaglUtide real-world evidence (SURE) Germany","author":"Menzen","year":"2023","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.diabres.2023.111018_b0170","doi-asserted-by":"crossref","DOI":"10.1111\/dom.15045","article-title":"Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE France multicentre, prospective, observational study","author":"Mohammedi","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.diabres.2023.111018_b0175","doi-asserted-by":"crossref","first-page":"e002619","DOI":"10.1136\/bmjdrc-2021-002619","article-title":"Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups","volume":"10","author":"Yale","year":"2022","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.diabres.2023.111018_b0180","doi-asserted-by":"crossref","first-page":"e14655","DOI":"10.1111\/dme.14655","article-title":"Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: real-world data from a diabetes out-patient clinic","volume":"38","author":"Hansen","year":"2021","journal-title":"Diabet. Med."},{"key":"10.1016\/j.diabres.2023.111018_b0185","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s40618-022-01799-2","article-title":"Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients","volume":"45","author":"Marzullo","year":"2022","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.diabres.2023.111018_b0190","first-page":"2283","article-title":"Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain","author":"Garcia de Lucas","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.diabres.2023.111018_b0195","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s13300-022-01313-0","article-title":"Effectiveness and safety of once-weekly semaglutide in Japanese patients with type 2 diabetes in treatment intensification: A retrospective observational single-center study","volume":"13","author":"Yamada","year":"2022","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.diabres.2023.111018_b0200","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s13300-022-01218-y","article-title":"Effectiveness in real world of once weekly semaglutide in people with type 2 diabetes: Glucagon-like peptide receptor agonist na\u00efve or switchers from other glucagon-like peptide receptor agonists: Results from a retrospective observational study in Umbria","volume":"13","author":"Di Loreto","year":"2022","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.diabres.2023.111018_b0205","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s13300-021-01010-4","article-title":"Outcomes in GLP-1 RA-Experienced patients switching to once-weekly semaglutide in a real-world setting: the retrospective, observational EXPERT study","volume":"12","author":"Lingvay","year":"2021","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.diabres.2023.111018_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645617","article-title":"Efficacy of semaglutide in a subcutaneous and an oral formulation","volume":"12","author":"Meier","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.diabres.2023.111018_b0215","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s13300-018-0424-2","article-title":"A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving 1\u20132 oral anti-diabetic drugs","volume":"9","author":"Witkowski","year":"2018","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.diabres.2023.111018_b0220","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.diabres.2023.111018_b0225","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3389\/fphar.2018.00576","article-title":"Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Shi","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.diabres.2023.111018_b0230","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra","year":"2022","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.diabres.2023.111018_b0235","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s13142-015-0353-9","article-title":"Effects on cardiovascular risk factors of weight losses limited to 5\u201310%","volume":"6","author":"Brown","year":"2016","journal-title":"Transl. Behav. Med."},{"key":"10.1016\/j.diabres.2023.111018_b0240","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.diabres.2023.111018_b0245","article-title":"Semaglutide for the treatment of type two Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes","volume":"102511","author":"Zaazouee","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.diabres.2023.111018_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2022.100944","article-title":"The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis","author":"Alhindi","year":"2022","journal-title":"Contemp. Clin. Trials Commun."}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723007817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723007817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:19:47Z","timestamp":1787429987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822723007817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":50,"alternative-id":["S0168822723007817"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2023.111018","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist na\u00efve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2023.111018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111018"}}